Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, FVT

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference


SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.

A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

SOURCE Heron Therapeutics, Inc.


These press releases may also interest you

at 08:15
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has set the record date for the...

at 08:15
New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged
Reprieve Cardiovascular, Inc. (?Reprieve'), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart...

at 08:11
Eating disorders symposium a groundbreaking success
The International Association of Eating Disorder Professionals (iaedptm) 2024 Symposium marked a significant milestone, reflecting growth and renewed commitment within the field of eating disorder treatment. The event showcased an impressive array of...

at 08:10
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific...

at 08:10
bioAffinity Technologies News Update
bioAffinity Technologies, Inc. shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month Sales of CyPath® Lung, our noninvasive diagnostic test for the early detection of lung cancer, continue to climb, with April sales up 21% over...

at 08:07
Lindus Health and University of Oxford Publish Study Citing Key Strategies to Foster Diversity in Clinical Trial Participation
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, announced the results of a study examining the motivators and deterrents of clinical trial participation among ethnic minorities. The...

More news about Health...


News published on and distributed by: